Curemark, LLC Email Format
Biotechnology ResearchNew York, United States11-50 Employees
Curemark, LLC is a clinical-stage biotechnology company based in Rye, New York, focused on developing therapies for neurological and developmental disorders. Its pipeline includes treatments for autism spectrum disorder, ALS, addiction, ADHD, schizophrenia, and Parkinson’s disease. The company emphasizes addressing underlying causes rather than solely managing symptoms, with its lead investigational therapy aimed at enzyme deficiencies linked to autism. Operating in the biotechnology research sector, Curemark pursues a science-driven, patient-focused approach to discovering targeted, brain-focused therapies. In June 2024, the company announced that its CEO would present at the Goldman Sachs Global Healthcare Conference, signaling external engagement with investors and the broader medical community.